VBIV- A lot of Insider Buying
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (VBIV) (VBV.TO) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 common shares, which included 2,100,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares at a price to the public of US$3.05 per share.
Please check future if this stock would fit into your investment portfolio, for a buy at this time. I see $4.00 to $4.20 in short term run. Good luck.
Please check future if this stock would fit into your investment portfolio, for a buy at this time. I see $4.00 to $4.20 in short term run. Good luck.
Haftungsausschluss
Die Informationen und Veröffentlichungen sind nicht als Finanz-, Anlage-, Handels- oder andere Arten von Ratschlägen oder Empfehlungen gedacht, die von TradingView bereitgestellt oder gebilligt werden, und stellen diese nicht dar. Lesen Sie mehr in den Nutzungsbedingungen.